within Pharmacolibrary.Drugs.ATC.C;

model C01DX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.3,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01DX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Prenylamine is a calcium channel blocker that was once used for the treatment of angina pectoris. It acts by inhibiting catecholamine storage and release, resulting in vasodilation and reduction in cardiac workload. Prenylamine has been withdrawn from most markets due to reports of cardiac arrhythmias and safety concerns, and is not currently approved or in clinical use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration in healthy adults as direct human PK data is not available in literature.</p><h4>References</h4><ol><li><p>Gietl, Y, et al., &amp; Mutschler, E (1990). Single- and multiple-dose pharmacokinetics of R-(-)-and S-(+)-prenylamine in man. <i>European journal of clinical pharmacology</i> 38(6) 587–593. DOI:<a href=&quot;https://doi.org/10.1007/BF00278587&quot;>10.1007/BF00278587</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2373134/&quot;>https://pubmed.ncbi.nlm.nih.gov/2373134</a></p></li><li><p>Schmidt, EK, et al., &amp; Dengler, HJ (1992). A gas chromatographic/mass spectrometric assay for prenylamine suitable for pharmacokinetic studies of the racemate and the enantiomers. <i>Biological mass spectrometry</i> 21(2) 103–108. DOI:<a href=&quot;https://doi.org/10.1002/bms.1200210208&quot;>10.1002/bms.1200210208</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1606181/&quot;>https://pubmed.ncbi.nlm.nih.gov/1606181</a></p></li><li><p>Kraemer, T, et al., &amp; Maurer, HH (2003). Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS. <i>Journal of analytical toxicology</i> 27(2) 68–73. DOI:<a href=&quot;https://doi.org/10.1093/jat/27.2.68&quot;>10.1093/jat/27.2.68</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12669999/&quot;>https://pubmed.ncbi.nlm.nih.gov/12669999</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01DX02;
